Asset Details
Do you wish to reserve the book?
Altitude illnesses
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Altitude illnesses
Do you wish to request the book?
Altitude illnesses
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Altitude illnesses
2024
Overview
Millions of people visit high-altitude regions annually and more than 80 million live permanently above 2,500 m. Acute high-altitude exposure can trigger high-altitude illnesses (HAIs), including acute mountain sickness (AMS), high-altitude cerebral oedema (HACE) and high-altitude pulmonary oedema (HAPE). Chronic mountain sickness (CMS) can affect high-altitude resident populations worldwide. The prevalence of acute HAIs varies according to acclimatization status, rate of ascent and individual susceptibility. AMS, characterized by headache, nausea, dizziness and fatigue, is usually benign and self-limiting, and has been linked to hypoxia-induced cerebral blood volume increases, inflammation and related trigeminovascular system activation. Disruption of the blood–brain barrier leads to HACE, characterized by altered mental status and ataxia, and increased pulmonary capillary pressure, and related stress failure induces HAPE, characterized by dyspnoea, cough and exercise intolerance. Both conditions are progressive and life-threatening, requiring immediate medical intervention. Treatment includes supplemental oxygen and descent with appropriate pharmacological therapy. Preventive measures include slow ascent, pre-acclimatization and, in some instances, medications. CMS is characterized by excessive erythrocytosis and related clinical symptoms. In severe CMS, temporary or permanent relocation to low altitude is recommended. Future research should focus on more objective diagnostic tools to enable prompt treatment, improved identification of individual susceptibilities and effective acclimatization and prevention options.
Acute or chronic exposure to elevations above 2,500 m can lead to altitude illnesses, including acute mountain sickness, high-altitude cerebral or pulmonary oedema, and chronic mountain sickness. In this Primer, Gatterer et al. summarize the epidemiology and pathophysiology of these disorders, discuss diagnosis, prevention and treatment, and highlight areas for future research.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Acclimatization - physiology
/ Altitude
/ Altitude Sickness - complications
/ Altitude Sickness - epidemiology
/ Altitude Sickness - physiopathology
/ Brain Edema - physiopathology
/ Edema
/ Humans
/ Hypertension, Pulmonary - epidemiology
/ Hypertension, Pulmonary - etiology
/ Hypertension, Pulmonary - physiopathology
/ Medicine
/ Primer
/ Pulmonary Edema - epidemiology
